The effect of caffeine dose on caffeine and paraxanthine changes in serum and saliva and CYP1A2 enzyme activity in athletes: a randomized placebo-controlled crossover trial

被引:0
|
作者
Glowka, Natalia [1 ]
Malik, Jakub [2 ]
Aniola, Jacek [3 ]
Zawieja, Emilia E. [3 ]
Chmurzynska, Agata [3 ]
Durkalec-Michalski, Krzysztof [1 ,4 ]
机构
[1] Poznan Univ Phys Educ, Dept Sports Dietet, PL-61871 Poznan, Poland
[2] Poznan Univ Phys Educ, Dept Pedag, Poznan, Poland
[3] Poznan Univ Life Sci, Dept Human Nutr & Dietet, Poznan, Poland
[4] Charles Univ Prague, Fac Phys Educ & Sport, Sport Sci Biomed Dept, Prague, Czech Republic
关键词
Enzyme activity; Ergogenic support; High-intensity functional training; Metabolism; Sports dietetics; Supplementation; GENETIC POLYMORPHISMS; IN-VIVO; EXERCISE; PERFORMANCE; PLASMA; PHARMACOKINETICS; RATIO; METABOLISM; SMOKING; IMPACT;
D O I
10.1186/s12986-024-00863-3
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
BackgroundAlthough caffeine (CAF) supplementation has been shown to improve exercise performance, its dose-dependent effect on CAF metabolism has not been sufficiently investigated. The aim of this study was to evaluate the effects of 3, 6 and 9 mg of CAF/kgBM on changes of CAF and paraxanthine (PRX) in the serum and saliva at four time-points.MethodsIn a randomized, double-blind, placebo-controlled crossover design, acute pre-exercise supplementation in 26 moderately-trained athletes, participating in high-intensity functional training (HIFT), was examined. The study protocol involved CAF/PRX biochemical analyses of serum and saliva with respect to CYP1A2 polymorphism and CYP1A2 enzyme activity.ResultsDespite significant differences between the serum and saliva levels of CAF and PRX, there was no difference in the PRX/CAF ratio. The interaction effect of dose and time-points for PRX concentration was revealed. The main effects of dose were observed for CAF and the PRX/CAF ratio. The main effect of time-points was registered only for serum CAF.ConclusionsDose- and time-dependent effect of CAF supplementation on CAF and PRX in the serum and saliva of athletes was confirmed, but there was no effect of the CAF dose on CYP1A2 enzyme activity, nor was there an interaction of CYP1A2 with enzyme inducibility. The CAF/PRX correlation indicated the possibility of interchangeable use of serum and/or saliva analyses in exercise studies.Clinical trial registrationThis trial was registered prospectively at ClinicalTrials.gov (NCT03822663, registration date: 30/01/2019).
引用
收藏
页数:16
相关论文
共 40 条
  • [31] Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial
    Vanpouille, Christophe
    Lisco, Andrea
    Grivel, Jean-Charles
    Bassit, Leda C.
    Kauffman, Robert C.
    Sanchez, Jorge
    Schinazi, Raymond F.
    Lederman, Michael M.
    Rodriguez, Benigno
    Margolis, Leonid
    CLINICAL INFECTIOUS DISEASES, 2015, 60 (11) : 1708 - 1714
  • [32] Effect of Vitamin E on Serum Levels of Vascular Endothelial Growth Factor and Angiopoietin-1 in Women with Polycystic Ovary Syndrome: A Pilot Randomized, Placebo-Controlled Trial
    Shirazi, Shabnam
    Gargari, Bahram Pourghassem
    Izadi, Azimeh
    Taghizadeh, Shiva
    Parizad, Marziyeh
    INTERNATIONAL JOURNAL OF FERTILITY & STERILITY, 2021, 15 (01) : 44 - 50
  • [33] A Randomized, Triple-blind Placebo-controlled Trial to Determine the Effect of Saffron on the Serum Levels of MMP-9 and TIMP-1 in Patients with Multiple Sclerosis
    Sakha, Fatemeh Ghasemi
    Saeen, Amirreza Azimi
    Moazzeni, Seyed Mohammad
    Etesam, Farnaz
    Vaezi, Gholamhassan
    IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2020, 19 (03) : 297 - 304
  • [34] Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial
    Roshanravan, Neda
    Mahdavi, Reza
    Alizadeh, Effat
    Jafarabadi, Mohammad Asghari
    Hedayati, Mehdi
    Ghavami, Abed
    Alipour, Shahriar
    Alamdari, Naimeh Mesri
    Barati, Meisam
    Ostadrahimi, Alireza
    HORMONE AND METABOLIC RESEARCH, 2017, 49 (11) : 886 - 891
  • [35] Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial
    Gumbiner, Barry
    Esteves, Brooke
    Dell, Vanessa
    Joh, Tenshang
    Garzone, Pamela D.
    Forgie, Alison
    Udata, Chandrasekhar
    ENDOCRINE, 2018, 62 (02) : 371 - 380
  • [36] Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
    Pete Schmidt
    Jean Gong
    Kristin Narayan
    Deepali Gupta
    Frank Engler
    Yong Li
    Amanda Copans
    Ed Campanaro
    Infectious Diseases and Therapy, 2023, 12 : 1365 - 1377
  • [37] Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
    Schmidt, Pete
    Gong, Jean
    Narayan, Kristin
    Gupta, Deepali
    Engler, Frank
    Li, Yong
    Copans, Amanda
    Campanaro, Ed
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (05) : 1365 - 1377
  • [38] IMI2-PainCare-BioPain-RCT2 protocol: a randomized, double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity
    Leone, Caterina
    Di Stefano, Giulia
    Di Pietro, Giuseppe
    Bloms-Funke, Petra
    Boesl, Irmgard
    Caspani, Ombretta
    Chapman, Sonya C.
    Finnerup, Nanna Brix
    Garcia-Larrea, Luis
    Li, Tom
    Goetz, Marcus
    Mouraux, Andre
    Pelz, Bernhard
    Pogatzki-Zahn, Esther
    Schilder, Andreas
    Schnetter, Erik
    Schubart, Karin
    Tracey, Irene
    Troconiz, Inaki F.
    Van Niel, Hans
    Hernandez, Jose Miguel Vela
    Vincent, Katy
    Vollert, Jan
    Wanigasekera, Vishvarani
    Wittayer, Matthias
    Phillips, Keith G.
    Truini, Andrea
    Treede, Rolf-Detlef
    TRIALS, 2022, 23 (01)
  • [39] Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial
    Wu, Jingying
    Zhou, Renpeng
    Zhang, Qian
    Zhang, Qin
    Qin, Huiling
    Ye, Zi
    Xu, Yimei
    Feng, Sheng
    Shu, Chang
    Shen, Yu
    Fan, Yang
    Wang, Quanren
    Du, Yijun
    Hu, Wei
    DIABETES OBESITY & METABOLISM, 2024, 26 (03) : 901 - 910
  • [40] IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET)
    Nochi, Zahra
    Pia, Hossein
    Bloms-Funke, Petra
    Boesl, Irmgard
    Caspani, Ombretta
    Chapman, Sonya C.
    Fardo, Francesca
    Genser, Bernd
    Goetz, Marcus
    Kostenko, Anna V.
    Leone, Caterina
    Li, Thomas
    Mouraux, Andre
    Pelz, Bernhard
    Pogatzki-Zahn, Esther
    Schilder, Andreas
    Schnetter, Erik
    Schubart, Karin
    Stouffs, Alexandre
    Tracey, Irene
    Troconiz, Inaki F.
    Truini, Andrea
    Van Niel, Johannes
    Vela, Jose Miguel
    Vincent, Katy
    Vollert, Jan
    Wanigasekera, Vishvarani
    Wittayer, Matthias
    Tankisi, Hatice
    Finnerup, Nanna B.
    Phillips, Keith G.
    Treede, Rolf-Detlef
    TRIALS, 2022, 23 (01)